Motley Fool Asset Management LLC Sells 310 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Motley Fool Asset Management LLC lessened its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 9.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,931 shares of the medical research company’s stock after selling 310 shares during the quarter. Motley Fool Asset Management LLC’s holdings in Exact Sciences were worth $217,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Strategic Blueprint LLC boosted its position in shares of Exact Sciences by 3.1% in the third quarter. Strategic Blueprint LLC now owns 5,449 shares of the medical research company’s stock valued at $372,000 after acquiring an additional 163 shares during the period. Valley National Advisers Inc. lifted its position in Exact Sciences by 29.5% during the third quarter. Valley National Advisers Inc. now owns 773 shares of the medical research company’s stock worth $53,000 after purchasing an additional 176 shares during the period. Cullen Frost Bankers Inc. lifted its position in Exact Sciences by 40.0% during the third quarter. Cullen Frost Bankers Inc. now owns 700 shares of the medical research company’s stock worth $48,000 after purchasing an additional 200 shares during the period. Nisa Investment Advisors LLC lifted its position in Exact Sciences by 0.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 37,200 shares of the medical research company’s stock worth $2,752,000 after purchasing an additional 205 shares during the period. Finally, Xponance Inc. lifted its position in Exact Sciences by 1.8% during the third quarter. Xponance Inc. now owns 13,073 shares of the medical research company’s stock worth $892,000 after purchasing an additional 235 shares during the period. Institutional investors own 88.82% of the company’s stock.

Insiders Place Their Bets

In other Exact Sciences news, EVP Sarah Condella sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $70.00, for a total transaction of $140,000.00. Following the transaction, the executive vice president now directly owns 71,787 shares in the company, valued at approximately $5,025,090. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Exact Sciences news, EVP Sarah Condella sold 2,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $70.00, for a total transaction of $140,000.00. Following the transaction, the executive vice president now directly owns 71,787 shares in the company, valued at approximately $5,025,090. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin T. Conroy sold 14,791 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $908,611.13. Following the transaction, the chief executive officer now owns 1,224,357 shares in the company, valued at $75,212,250.51. The disclosure for this sale can be found here. In the last three months, insiders have sold 69,113 shares of company stock worth $4,165,273. Corporate insiders own 1.30% of the company’s stock.

Exact Sciences Stock Up 0.1 %

Shares of EXAS stock opened at $58.85 on Friday. Exact Sciences Co. has a one year low of $56.05 and a one year high of $100.77. The business’s 50 day simple moving average is $63.44 and its 200 day simple moving average is $64.95. The company has a current ratio of 2.32, a quick ratio of 2.07 and a debt-to-equity ratio of 0.74.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.26. The firm had revenue of $646.89 million for the quarter, compared to analysts’ expectations of $638.83 million. Exact Sciences had a negative return on equity of 6.60% and a negative net margin of 8.17%. The company’s revenue for the quarter was up 17.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.72) EPS. As a group, equities analysts anticipate that Exact Sciences Co. will post -0.86 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on EXAS shares. Citigroup reissued a “buy” rating and set a $100.00 target price on shares of Exact Sciences in a research note on Wednesday, April 3rd. Canaccord Genuity Group lowered their target price on Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. TheStreet downgraded Exact Sciences from a “c-” rating to a “d+” rating in a research note on Monday, February 26th. Benchmark raised Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 target price for the company in a research note on Tuesday, January 2nd. Finally, William Blair reissued an “outperform” rating on shares of Exact Sciences in a research note on Thursday, February 22nd. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.44.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.